Dal­cor taps new CEO Fouzia Laghris­si-Th­ode as piv­otal PhI­II looms; Kel­ly Mar­tin set­tles in at No­van; Ed­ward Stew­art takes over Com­mense

→ As­traZeneca vet Fouzia Laghris­si-Th­ode will be lead­ing Dal­Cor Phar­ma­ceu­ti­cals through pa­tient en­roll­ment in­to its piv­otal Phase III tri­al. The new­ly mint­ed CEO has her work cut out for her — Lon­don-based Dal­Cor is try­ing to prove that dal­cetrapib, a CETP in­hibitor Roche aban­doned, has a strong car­dio ben­e­fit for a sub­group of pa­tients with a cer­tain geno­type by test­ing it in 6000 peo­ple. Laghris­si-Th­ode be­gan tack­ling this field at Roche, where she was a fran­chise leader for sev­er­al drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER